MEK inhibitors for the treatment of NRAS mutant melanoma
Saro Sarkisian,1 Diwakar Davar2 1Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, PA, USA; 2Division of Hematology-Oncology, Hillman Cancer Center and University of Pittsburgh, Pittsburgh, PA, USA Abstract: Melanoma is increasing rapidly in incidence and prevalence, esp...
Main Authors: | Sarkisian S, Davar D |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-08-01
|
Series: | Drug Design, Development and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/mek-inhibitors-for-the-treatment-of-nras-mutant-melanoma-peer-reviewed-article-DDDT |
Similar Items
-
Exploring the In Vitro and In Vivo Therapeutic Potential of BRAF and MEK Inhibitor Combination in NRAS-Mutated Melanoma
by: Heike Niessner, et al.
Published: (2023-11-01) -
Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for <i>BRAF</i>-Mutant Melanoma
by: Omid Hamid, et al.
Published: (2019-10-01) -
Phase I pharmacokinetic study of an oral, small-molecule MEK inhibitor tunlametinib in patients with advanced NRAS mutant melanoma
by: Qian Zhao, et al.
Published: (2022-11-01) -
Case report: Therapeutic potential of T-VEC in combination with MEK inhibitors in melanoma patients with NRAS mutation
by: Sonja C. S. Simon, et al.
Published: (2023-03-01) -
Efficacy of Targeted Radionuclide Therapy Using [<sup>131</sup>I]ICF01012 in 3D Pigmented BRAF- and NRAS-Mutant Melanoma Models and In Vivo NRAS-Mutant Melanoma
by: Hussein Akil, et al.
Published: (2021-03-01)